Non-Animal Models (NAMs) in Practice: Approaches for Preclinical Safety and Efficacy Screening

ستغطي هذه الندوة الافتراضية ما يلي:

UK, US, and EU perspectives on New Approach Methodologies.

Case studies spanning:

Whole blood bioassays.
Isolated primary immune cell assays.
Our ex vivo skin explant platform.
Reconstructed skin models for efficacy and tolerance tests.
Applications of precision cut lung slices for respiratory research without animal testing.

قم بالاشتراك للتسجيل بالندوة

التاريخ: 2026-10-15

الوقت: 11:00 AM (EDT)

اللغة : English

الرسوم: Free

المواضيع: Lab Testing

المتحدثون: Kelsey Retting, Arnaud Huard, Callum O Kane

تسجيل الاشتراك

ما ستتعلمه في هذه الندوة

Join us on October 15, 2026 (1700 CEST / 1500 UTC) for our live webinar: Non-Animal Models in Practice: Approaches for Preclinical Safety and Efficacy Screening.

In this webinar, we’ll cover:

The history and status of NAMs in EU, UK, and US preclinical testing.
Ex vivo platform data from human blood bioassays.
Dermal safety and efficacy testing without animal models.
Respiratory indication testing using human-relevant alternatives.

Equip your team with a clearer view of where non-animal approaches really stand today, and where they may head next.

نبذة عن المتحدثين

Kelsey Retting

Senior BD Manager, QIMA Life Sciences

Kelsey is a Senior Business Development Manager at QIMA Life Sciences with a PhD in Biological Chemistry from UCLA and a career spanning drug discovery, in vitro pharmacology, and translational research. She has worked across large pharmaceutical companies, biotechnology firms, and start-ups, developing assays and complex 3D tissue-engineered and bioprinted models for disease modeling, compound screening, and preclinical development.

Arnaud Huard

Study Director, QIMA Bioalternatives

Arnaud is a study directeur at QIMA Bioalternatives, specialised in immuno-inflammation research. He achieved a PhD on resolution of inflammation in Frankfurt, followed by two postdocs in Geneva, working on skin inflammation, psoriasis and inflammasome biology, in the context of hyperinflammatory syndrome.

Callum O Kane

Market Segment Lead, QIMA Life Sciences

Callum began his research career at Queen's University Belfast, gaining a PhD in pathogen epigenetics, before joining the Axis Bio science team. He spent five years with Axis, leading cell culture projects and R&D, and acting as study director for in vivo and in vitro research projects, before joining QIMA Life Sciences.

مزيد من القراءة

نبذة عن المنظمة

QIMA قائدعالمية في خدمات ضمان الجودة وحلول الامتثال، وتساعد الشركات على تصنيع منتجات يمكن للمستهلكين الوثوق بها من خلال الفحص والاختبار والتدقيق والاعتماد. ومن خلال الجمع بين الخبرة البشرية الميدانية والتكنولوجيا الذكية، تدعم QIMA أكثر من 30,000 شركة في قطاعات السلع الاستهلاكية، والأغذية والزراعة، ومستحضرات التجميل والعناية الشخصية، والأدوية والتكنولوجيا الحيوية، في أكثر من 100 دولة

ندوات إلكترونية أخرى ذات صلة

إظهار الكل